TALWIN NX Drug Patent Profile
✉ Email this page to a colleague
When do Talwin Nx patents expire, and when can generic versions of Talwin Nx launch?
Talwin Nx is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in TALWIN NX is naloxone hydrochloride; pentazocine hydrochloride. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride; pentazocine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Talwin Nx
A generic version of TALWIN NX was approved as naloxone hydrochloride; pentazocine hydrochloride by WATSON LABS on January 21st, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TALWIN NX?
- What are the global sales for TALWIN NX?
- What is Average Wholesale Price for TALWIN NX?
Summary for TALWIN NX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 1 |
| DailyMed Link: | TALWIN NX at DailyMed |
Recent Clinical Trials for TALWIN NX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Stanley Medical Research Institute | Phase 2 |
| Mclean Hospital | Phase 2 |
US Patents and Regulatory Information for TALWIN NX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | TALWIN NX | naloxone hydrochloride; pentazocine hydrochloride | TABLET;ORAL | 018733-001 | Dec 16, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TALWIN NX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | TALWIN NX | naloxone hydrochloride; pentazocine hydrochloride | TABLET;ORAL | 018733-001 | Dec 16, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TALWIN NX
See the table below for patents covering TALWIN NX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| United Kingdom | 1000506 | ⤷ Sign Up | |
| Denmark | 103236 | ⤷ Sign Up | |
| Germany | 1445153 | 1,2,3,4,5,6-HEXAHYDRO-3-(3-METHYL-2BUTENYL)-6,11-DIMETHYL-8-HYDROXY-2,6METHANO-3-BENZAZOCIN, SEINE SAEUREADDITIONSSALZE UND VERFAHREN ZU IHRER HERSTELLUNG | ⤷ Sign Up |
| Austria | 252248 | ⤷ Sign Up | |
| Belgium | 611000 | ⤷ Sign Up | |
| Netherlands | 6705466 | ⤷ Sign Up | |
| Brazil | 6134479 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TALWIN NX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
